Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme

Molecular Therapy

Volumn 6, Issue 5, 2002, Pages 601-608

  Raben, Nina ^a   Jatkar, Tejas ^a   Lee, Alicia ^a   Lu, Nina ^a   Dwivedi, Sunita ^a   Nagaraju, Kanneboyina ^a   Plotz, Paul H ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Acid glocosidase; Knockout; Myopathy; Pompe disease; Transgenic

Indexed keywords

GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; TETRACYCLINE; ALPHA GLUCOSIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOMYOPATHY; CLEARANCE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ENZYME ACTIVITY; ENZYME REPLACEMENT; GENE THERAPY; GENETIC CODE; GLYCOGEN STORAGE DISEASE TYPE 2; HEART MUSCLE; LYSOSOME STORAGE DISEASE; MOUSE; MOUSE MUTANT; MUSCLE CELL; MYOPATHY; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVERSAL REACTION; SKELETAL MUSCLE; TRANSGENE; WILD TYPE; ANIMAL; CYTOLOGY; FEMALE; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; MUTATION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALIA;

ALPHA-GLUCOSIDASES; ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHIES; FEMALE; GENE TRANSFER TECHNIQUES; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUTATION; MYOCARDIUM; PHENOTYPE; TRANSGENES;

EID: 0036853028     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)90716-1     Document Type: Article

References (35)

1. Hirschhorn, R., and Reuser, A.J. (2000). Glycogen storage disease type II: acid glucosidase (acid maltase) deficiency. In: The Metabolic and molecular Basis of Inherited Disease (C. R. Scriver et al., Eds.), pp. 3389-3420. McGraw-Hill, New York.
2. Raben, N., Plotz, P., and Byrne, B.J. (2002). Acid α-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr. Mol. Med. 2: 145-166.
3. Hoefsloot, L. H., et al. (1990). Expression and routeing of human lysosomal α-glucosidase in transiently transfected mammalian cells. Biochem. J. 272: 485-492.
4. Wisselaar, H. A., Kroos, M. A., Hermans, M. M., van Beeumen, J., and Reuser, A.J. (1993). Structural and functional changes of lysosomal acid α-glucosidase during intracellular transport and maturation. J. Biol. Chem. 268: 2223-2231.
5. Kornfeld, S., and Mellman, I. (1989). The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5: 483-525.
6. Kornfeld, S. (1992). Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu. Rev. Biochem. 61: 307-330.
7. Le Borgne, R., and Hoflack, B. (1998). Protein transport from the secretory to the endocytic pathway in mammalian cells. Biochim. Biophys. Acta 1404: 195-209.
8. Doray, B., Bruns, K., Ghosh, P., and Kornfeld, S. (2002). Interaction of the cation-dependent mannose 6-phosphate receptor with GGA proteins. J. Biol. Chem. 277: 18477-18482.
9. Zhu, Y., Doray, B., Poussu, A., Lehto, V.P., and Kornfeld, S. (2001). Binding of GGA2 to the lysosomal enzyme sorting motif of the mannose 6-phosphate receptor. Science 292: 1716-1718.
10. Van den Hout, H. H., et al. (2001). Enzyme therapy for Pompe disease with recombinant human α-glucosidase from rabbit milk. J. Inherit. Metab. dis. 24: 266-274.
11. Van den Hout, H. H., et al. (2000). Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet 356: 397-398.
12. Amalfitano, A., et al. (2001). Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 3: 132-138.
13. Eng, C. M., et al. (2001). Safety and efficacy of recombination human α-galactosidase A - replacement therapy in Fabry's disease. N. Engl. J. 345: 9-16.
14. Schiffmann, R., et al. (2001). Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743-2749.
15. Kakkis, E. D., et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344: 182-188.
16. Miranda, S. R., et al. (2000). Infusion of recombinant human acid sphingomylinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 14: 1988-1995.
17. Turner, C. T., Hopwood, J. JU., and Brooks, D. A. (2000). Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of α-L-induronidase in immunized rats. Mol. Genet. Metab. 69: 277-285.
18. Van Hove, J. L., Yang, H. W., Wu, J. Y., Brady, R. O., and Chen, Y. T. (1996). High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc. Natl. Acad. Sci. USA 93: 65-70.
19. Bijvoet, A. G., et al. (1998). Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, and correction of enzyme deficiency in GSDII KO mice. Hum. Mol. Genet. 7: 1815-1824.
20. Bijvoet, A. G., et al. (1999). Human acid α-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum. Mol. Genet. 8: 2145-2153.
21. Kikuchi, T., et al. (1998). Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J. Clin. Invest. 101: 827-833.
22. Neufeld, E.F. (1991). Lysosomal storage diseases. Annu. Rev. Biochem. 60: 257-280.
23. Reuser, A. J., et al. (1995). Glycogenosis type II (acid maltase deficiency). Muscle Nerve 35: 61-69.
24. Furth, P. A., et al. (1994). Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA 91: 9302-9306.
25. Kistner, A., et al. (1996). Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA 93: 10933-10938.
26. Raben, N., et al. (2001). Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum. Mol. Genet. 10: 2093-2147.
27. Raben, N., et al. (2001). A new approach to generate mice tolerant to recombinant human proteins. Am. J. Hum. Genet. 695(4), Abstract 2900.
28. Yu, Z., Redfren, C. S., and Fishman, G. I. (1996). Conditional transgene expression in the heart. Circ. Res. 79: 691-697.
29. Ausems, M.G., Berg, K., Beemer, F.A., and Wokke, J.H. (2000). Phenotypic expression of late-onset glycogen storage disease type II: identification of asymptomatic adults through family studies and review of reported families. Neuromuscul. Disord. 10: 467-471.
30. Simons, K., and Gruenberg, J. (2002). Rab proteins mediate Golgi transport of calveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 109: 1541-1550.
31. Choudhury, A., et al. (2002). Rab proteins mediate Golgi transport of calveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 109: 1541-1550.
32. Raben, N., et al. (1998). Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 273: 19086-19092.
33. Raben, N., Nagaraju, K., Lee, E., and Plotz, P. (2000). Modulation of disease severity in mice with targeted disruption of the acid α-glucosidase gene. Neuromuscul. Disord. 10: 283-291.
34. Ghersa, P., et al. (1998). Highly controlled gene expression using combinations of a tissue-specific promoter, recombinant adenovirus and a tetracycline-regulatable transcription factor. Gene Ther. 5: 1213-1220.
35. Hermans, M. M., Kroos, M. A., van Beeumen, J., Oostra, B. A., and Reuser, A.J. (1991). Human lysosomal α-glucosidase. Characterization of the catalytic sute. J. Biol. Chem. 266: 13507-13512.